Scalper1 News
Antibiotics specialist Tetraphase Pharmaceuticals (TTPH) stock crashed nearly 80% and got multiple downgrades Wednesday after the company’s lead drug, eravacycline, failed a clinical trial. Late Tuesday, Tetraphase said that in Ignite2, its phase-three clinical trial against complicated urinary tract infections (cUTI), eravacycline did not stack up against standard treatment levofloxacin, better known as Johnson & Johnson’s (JNJ) Levaquin. “We Scalper1 News
Scalper1 News